...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: A couple Q2 events for Zenith

Even though they are completely silent to us retail shareholders I can take solice that the trial contines without any stoppage, which is a great thing and DM mentioned at the last AGM that the Clinical investigators  stated by DM

from F6 at investor village

They're so excited, I can't help but be excited! So we're looking forward to moving this thing to the next stage, in this particular trial with Enzalutamide. It won't take very long to get data - we're talking - early data sets start showing up in (a) couple months, so we're very pleased!" (McCaffrey gushing....) 

with all this good news to date from the good DR's  no way BP does take a chance on this flier, heads would fly with management if they ZEN 3694 get away to a competitor

 

 

 

Share
New Message
Please login to post a reply